Core Viewpoint - The recent regulatory warning issued to Minsheng Securities by the Shenzhen Stock Exchange highlights significant compliance issues during the IPO sponsorship of Dija Pharmaceutical Group, raising concerns about the company's operational integrity and internal controls [3][4]. Group 1: Regulatory Issues - Minsheng Securities received a written warning from the Shenzhen Stock Exchange due to inadequate verification during the IPO process of Dija Pharmaceutical [3]. - The warning identified four main areas of concern regarding Dija Pharmaceutical's independence from its controlling shareholder, Disha Group, and related parties [4]. - Specific issues included failure to verify transaction details, lack of proper internal controls in sales and inventory management, and inaccuracies in accounting for returns [4]. Group 2: Financial Performance - According to the Q1 2025 report from Guolian Minsheng Securities, the company reported approximately 1.562 billion yuan in revenue, reflecting a year-on-year increase of 800.98% [4]. - The net profit attributable to shareholders was approximately 38 million yuan, indicating a turnaround from losses in the previous year [4].
民生证券因迪嘉药业IPO项目被警示 国联民生证券总裁葛小波怎么看？
Xin Lang Cai Jing·2025-05-12 09:36